Lilly - About the company
Lilly is a public company based in Indianapolis (United States), founded in 1876 by Eli Lilly. It operates as a Developer of traditional pharmaceutical medicines. Lilly has raised an undisclosed amount in funding. The company has 2124 active competitors, including 116 funded and 220 that have exited. Its top competitors include companies like AbbVie, Merck and Gilead.
Company Details
Developer of traditional pharmaceutical medicines. It produces medicines in oncology, cardiovascular, diabetes, critical care, neuroscience, men’s health, and musculoskeletal fields. In 2022, the company recorded annual revenues of $28.54B and a net profit of $6.24B.
- Website
- lilly.com
- Email ID
- *****@lilly.com
- Phone Number
- +1 **********
- Registered Address
- PLOT NO-92SECTOR 32 GURGAON, HARYANA, Haryana, India, 122001
Key Metrics
Founded Year
1876
Location
Indianapolis, United States
Stage
Public
Latest Funding Round
Investors
Ranked
6th among 2124 active competitors
Annual Revenue
$1B+ as on Dec 31, 2025
Employee Count
57,646 as on Sep 30, 2026
Investment & Acquisitions
Exit Details
Public
Legal entities associated with Lilly
Lilly is associated with 5 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
LILLY HQ ApS CIN: 41281782 , Denmark, Active | Apr 02, 2020 | - | - | |
LILLY A/S CIN: 29606668 , Denmark, Active | May 29, 2006 | - | - | |
Eli Lilly & Co CIN: 59478 , United States, Active | $1B+ (As on Dec 31, 2025) | 39000 (As on Dec 31, 2022) | - | |
ELI LILLY SERVICES INDIA PRIVATE LIMITED CIN: U72200KA2015FTC082300 , India, Active | Aug 17, 2015 | ₹1,000+ Cr (As on Mar 31, 2025) | 2872 (As on Jan 31, 2024) | |
ELI LILLY AND COMPANY (INDIA ) PRIVATE LIMITED CIN: U24239HR1993PTC034844 , India, Active | Mar 18, 1993 | ₹1,000+ Cr (As on Mar 31, 2025) | - |
Lilly's IPO details
Lilly got listed on Jan 06, 1978.
Click here to take a look at Lilly's IPO in detail
Sign up to download Lilly's company profile
Lilly's funding and investors
Lilly has raised funding over 9 rounds. Its first funding round was on Jun 28, 2007. Its latest funding round was a Post IPO round on 2020 for $*****. 1 investor participated in its latest round. Lilly has 13 institutional investors.
Here is the list of recent funding rounds of Lilly:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
2020 | 2822 | Post IPO | 7828 | 7615 | 7402 | 4581 |
Mar 03, 2019 | 9251581 | Conventional Debt | 4390543 | 9364430 | 2493671 | 9843167 |
Aug 01, 2018 | 8497269 | Grant (prize money) | 1774351 | 2543182 | 6507656 |
View details of Lilly's funding rounds and investors
Lilly's founders and board of directors
Founder? Claim ProfileThe founders of Lilly is Eli Lilly.
Here are the details of Lilly's key team members:
- Eli Lilly: Founder of Lilly. They are also an angel investor in 15 startups.
View details of Lilly's Founder profiles and Board Members
Lilly's employee count trend
Lilly has 57,646 employees as of Sep 26. Here is Lilly's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Lilly's Competitors and alternates
Top competitors of Lilly include AbbVie, Merck and Gilead. Here is the list of Top 10 competitors of Lilly, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 84/100 | |
2nd | Merck 1891, Rahway (United States), Public | Manufacturer of pharmaceutical products | - | 83/100 | |
3rd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 82/100 | |
4th | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 80/100 | |
5th | AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 77/100 | |
6th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 76/100 | |
7th | Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
8th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 72/100 | |
9th | Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 71/100 | |
10th | Pfizer 1849, New York City (United States), Public | Provider of pharmaceutical products for multiple disease treatments | - | 71/100 |
Looking for more details on Lilly's competitors? Click here to see the top ones
Lilly's Investments and acquisitions
Lilly has made 147 investments in companies including General Medicine and Circle Pharma. Lilly has also acquired 40 companies including Meridabio and AtaiBeckley.Here is the list of investments & acquisitions:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Oct 06, 2026 | Investments | 2023 | San Francisco (United States) | |
Sep 16, 2026 | Investments | 2014 | San Francisco (United States) | |
Sep 08, 2026 | Investments | 2017 | San Diego (United States) |
See all investments and acquisitions by Lilly
Reports related to Lilly
Here is the latest report on Lilly's sector:
News related to Lilly
Media has covered Lilly for a total of 638 events in the last 1 year, 353 of them have been about company updates and 59 about partnerships.
•
•
InnoCare Pharma advances commercialization and medicine developmentChina Daily•Oct 28, 2026•InnoCare, Lilly
•
Eli Lilly merging US, international units to form Lilly Global Markets in 2027Seeking Alpha•Oct 27, 2026•Lilly
•
•
Eli Lilly Presents First Clinical Data in Platinum-Sensitive Ovarian Cancer for Investigational FRα-Targeting ADCPR Newswire•Oct 24, 2026•Lilly
•
•
Lilly's Omvoh Meets Primary Endpoint in Pediatric Ulcerative Colitis Phase 3 StudyPR Newswire•Oct 19, 2026•Lilly
•
CHMP approves Lilly's Orforglipron as daily oral GLP-1 for weight loss that can be taken freelyPharmatech industria farmaceutica•Oct 19, 2026•Lilly
•
Eli Lilly's Obesity Drug Success: A $1,000 Investment Skyrockets to $18,637, Outperforming S&P 500Wall St.•Oct 16, 2026•Lilly
•
Lilly’s Foundayo wins EMA panel backing for obesity and type 2 diabetesPharmaceutical Technology•Oct 16, 2026•Lilly
Are you a Founder ?
FAQs about Lilly
Explore our recently published companies
- BraillEye - Al Ain based, 2017 founded, Public company
- Enzymecomms - 2018 founded, Unfunded company
- Kabra Extrusion Technik - Mumbai based, 1982 founded, Unfunded company
- Mashnu AI - 2026 founded, Unfunded company
- ADTANK - Japan based, 1971 founded, Funding Raised company
- Star Collection - Seed company
